Montreal / April 25, 2025 – Clinical researchers at the University of Montreal Hospital Center (CHUM) have published in the journal BMC Cancer the clinical protocol for human safety trials initiated...
March 08, 2025, The CHUM site is activated to begin patient recruitment for safety clinical trials with NexPlasmaGen medical technology Montreal / March 08, 2025 - The Centre hospitalier de l'Université de...
Montreal / September 19, 2024 - NexPlasmaGen wins the Corporate Livewire magazine's Innovation and Excellence Award - Cancer Treatment Technology Company of 2024 The Corporate LiveWire Innovation & Excellence Awards celebrate...
Montreal / August 8, 2024 - NexPlasmaGen is pleased to announce that Mr. David Uffer and Mr. Edward J. Dougherty have joined NexPlasmaGen! David Uffer, M.A, MBA joins NexPlasmaGen's Board of...
Montreal / April 19, 2024 - NexPlasmaGen is honored to announce that it has won GHP magazine's Best MedTech Oncology Business - Canada 2024 award. "GHP Magazine's Biotechnology Awards 2024” are...
Montreal / April 05, 2024 - NexPlasmaGen is pleased to announce that on February 6, 2024, the 2nd U.S. patent (US 11895763B2) was granted for its medical technology developed for...